J

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

Director CX Analytics & Optimization Technical Suite Lead

Full-Time
$188k - $282k/yr
Expert
Bachelor's, Master's, PhD
Pennsylvania, USA
RemoteMust reside in Pennsylvania, United States.

About the job

Requirements
  • Bachelor’s degree in computer science, engineering, information systems, or related technical field.
  • 10+ years of experience after Bachelor's degree (or 8+ years of experience after Master's degree) in software engineering, technical architecture, or enterprise platform delivery management.
  • 3+ years of experience as a Tech Lead, Technical Program Manager, Engineering Manager, or other roles involving managing a team of developers.
  • 6-8 years of experience leading people, including managing and developing high-performing teams and driving accountability across functions.
  • Demonstrated experience delivering enterprise‑scale analytics, reporting, or modeling platforms such as Power BI, In-house Marketing Mix Solution, and Predictive Analytics Products.
  • Hands-on experience with programming languages such as Python and R for analytics and data engineering, including working with cloud data platforms like Redshift and Snowflake for data sourcing, transformation, and integration into downstream analytics and modeling solutions.
  • Experience guiding technical architecture within complex, matrixed organizations.
  • Experience using Agile and Product Operating Model principles to drive alignment, autonomy, and outcome-focused delivery.
  • Proven ability to lead and mentor development teams and technical leaders.
  • 10-20% travel will be required.
Responsibilities
  • Set and drive the technical direction for Customer Analytics & Insights and Performance Analytics & Optimization teams in alignment with product strategy and enterprise priorities.
  • Collaborate with the Customer Analytics & Insights and Performance Analytics & Optimization CX Suite Leads to create value-focused roadmaps, defined to launch and enhance the technical capabilities to deliver the Customer Experience ambition
  • Own budget and resource allocation, making investment decisions across capabilities and teams to maximize impact and long-term value.
  • Translate product roadmaps into scalable technology architectures and development plans working closely with the Enterprise AI and Analytics & Automation Capability Leads to assess feasibility, identify dependencies, and mitigate risks
  • Ensure technical planning supports consistent KPI frameworks, governed measurement, and decision‑ready analytics across brands and channels.
  • Ensure development teams build scalable, secure, and reliable technology solutions that support: Conso lidated Insights Products, which are productized analytics and market research solutions that accelerate and standardize insight generation across customer segments and use cases.
  • Enterprise Reporting Products, which deliver standardized, decision-ready insights and governed KPIs to support executive, brand, field, and functional leadership. Supporting technology solutions include PowerBI.
  • Digital Analytics Products and In-house Marketing Mix Solution, which measure campaign performance, optimize marketing investment allocation, and deliver advanced modeling to drive ROI and engagement impact.
  • Predictive Analytics Products, which leverage advanced modeling to enhance targeting and engagement strategies.
  • Partner with leadership on workforce planning, capability development, and evolution of the operating model as capabilities mature.
  • Manage vendor partners, ensuring clear accountability, quality delivery and alignment to objectives.
  • Act as the primary technical point of accountability for both the Customer Analytics & Insights and Performance Analytics & Optimization suites, partnering with architects, security, and data teams to ensure compliance with organizational standards and regulatory expectations.
  • Work closely with Tech Leads, Capability Owners, development teams, and adjacent platform teams to coordinate roadmap dependencies, integrations, and architectural decisions.
  • Partner with the Suite Lead on product roadmap and strategy, ensuring technical architecture decisions are aligned with suite priorities, and collaborating with business teams to shape the product experience and translate user needs into scalable, high-impact solutions.
  • Represent the technical architecture, platforms, and delivery considerations of the Customer Analytics & Insights and Performance Analytics & Insights teams in domain, cross‑suite, and executive forums to drive alignment and resolve dependencies.
  • Collaborate with CX Data Tech Leads and Enterprise Data & AI Capability Leads to align on shared data infrastructure, integration standards, and AI/ML enablement — ensuring consistency across analytics platforms and driving coordinated delivery across the Customer Analytics & Insights and Performance Analytics & Optimization suites.
  • Lead resolution of technical cross-team issues affecting Customer Analytics & Insights and Performance Analytics & Insights performance or adoption
Desired Qualifications
  • Advanced degree in computer science, engineering, or related field preferred.
  • Experience in pharmaceutical or healthcare industries preferred.
  • Experience partnering closely with product leadership in a product-based operating model.
  • Experience working in rare disease or specialty brands, with strong understanding of unique stakeholder dynamics.

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $1.21 billion; Jazz raised full-year guidance to $4.68 billion.
  • Actio's ABS-1230 adds first-in-class KCNT1 epilepsy upside after the September 15, 2026 close.
  • Oncology revenue exceeded $1 billion in 2025, driven by Zepzelca and Ziihera.

What critics are saying

  • Xywav faces Lupin, Teva, and Tris patent fights; generic entry threatens 2027 cash flow.
  • Xywav and EPIDIOLEX still dominate value; one patent loss or safety issue would crush earnings.
  • Jazz paid $820 million for Actio before registrational proof; ABS-1230 can still fail.

What makes Jazz Pharmaceuticals unique

  • Ziihera launched August 2026, targeting $3B-$5B across HER2-positive tumors.
  • EPIDIOLEX holds exclusivity into the late 2030s and now funds four new trials.
  • Xywav's low-sodium oxybate formulation keeps narcolepsy patients despite generic Xyrem pressure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 1%

2 year growth

↑ 0%
Yahoo Finance
Sep 20th, 2026
Jazz Pharma raises zanidatamab peak sales target to $3B-$5B as oncology revenue hits $1B

Jazz Pharmaceuticals reported its oncology revenue surpassed $1 billion in 2025, marking a 32% year-over-year increase. The growth follows three recent product launches, including zanidatamab, Modeyso and Zepzelca's FORTE regimen. The company raised zanidatamab's estimated peak-sales opportunity to $3 billion-$5 billion. Jazz aims to increase HER2-directed treatment adoption in gastroesophageal cancer, where only 60% of eligible HER2-positive patients currently receive such therapy. Jazz estimates the US incidence of HER2-positive gastroesophageal adenocarcinoma at approximately 8,000 patients, with a labelled population of 3,000 to 4,000 patients. The company is also developing zanidatamab for biliary tract cancer, colorectal cancer, non-small cell lung cancer and breast cancer. Jazz maintains commercial investment whilst preserving financial flexibility for acquisitions across oncology, epilepsy and sleep disorders.

Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.